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Background: Adipose-derived stromal cells (ASCs) stimulated with vascular endothelial growth factor (VEGF) and
serum-deprived, are applied in the first in-man double-blind placebo-controlled MyStromalCell Trial, as a novel
therapeutic option for treatment of ischemic heart disease (IHD). This in vitro study explored the effect of VEGF and
serum deprivation on endothelial differentiation capacity of ASCs from healthy donors and IHD patients.
Methods: ASCs stimulated with rhVEGFA165 in serum-deprived medium for one to three weeks were compared
with ASCs in serum-deprived (2% fetal bovine serum) or complete medium (10% fetal bovine serum). Expression of
VEGF receptors, endothelial and stem cell markers was measured using qPCR, flow cytometry and
immunocytochemistry. In vitro tube formation and proliferation was also measured.
Results: ASCs from VEGF-stimulated and serum-deprived medium significantly increased transcription of transcription
factor FOXF1, endothelial marker vWF and receptor VEGFR1 compared with ASCs from complete medium. ASCs
maintained stem cell characteristics in all conditions. Tube formation of ASCs occurred in VEGF-stimulated and
serum-deprived medium. The only difference between healthy and patient ASCs was a variation in proliferation rate.
Conclusions: ASCs from IHD patients and healthy donors proved equally inclined to differentiate in endothelial
direction by serum-deprivation, however with no visible additive effect of VEGF stimulation. The treatment did not
result in complete endothelial differentiation, but priming towards endothelial lineage.
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Ischemic heart disease (IHD) is the leading cause of death
in industrialized countries and the incidence is continuously
increasing due to the ageing population and ongoing obes-
ity pandemic [1,2]. Despite improved medical treatment
and interventional therapy in acute phases of the disease, a
large number of patients still develop chronic heart disease
or heart failure. It is of great interest to devise novel treat-
ment options for those IHD patients who do not respond* Correspondence: Annette.Ekblond@regionh.dk
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reproduction in any medium, provided the orsufficiently to conventional care. One relatively new ap-
proach is the use of stem cell therapy with the potential to
support regeneration of the damaged myocardium [3,4].
Mesenchymal stromal cells (MSCs) are unspecialized
cells characterized by their ability to differentiate into vari-
ous tissue-specific cells and to preserve the potential for
both differentiation and self-renewal through multiple cell
divisions [5]. They have been shown to possess regenerative
abilities including differentiation and incorporation into re-
generating tissue, immunomodulation, inhibition of apop-
tosis and scarring, stimulation of progenitor cells, and
contribution to angiogenesis [6,7]. MSCs have been identi-
fied in various tissues in the human body including both
adipose-derived stromal cells (ASCs/ADSCs) and bonetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rently the most thoroughly investigated, however, ASCs
possess comparative abilities, and are harvested with min-
imally invasive liposuction with a higher yield of stem cells
per harvest, and proliferate faster during ex vivo expansion.
This makes them a more preferable source of stem cells for
regenerative therapies [8-12].
A prerequisite for tissue regeneration in the ischemic
heart is the reestablishment of blood supply to the infarct
area. Therefore the effect of stem cell therapy is bound to
be promoted by the vasculogenic or angiogenic ability of
stem cells, and possibly so by their endothelial differenti-
ation potential [13]. In order to increase the effect of stem
cell treatment, it could prove beneficial to precondition
the stem cells, in order to enhance these abilities.
It has been shown that BMSCs can differentiate towards
an endothelial lineage by stimulation with vascular endo-
thelial growth factor (VEGF), traditionally in combination
with serum deprivation to suppress proliferation [14-17].
Our group has conducted a clinical study using BMSCs
preconditioned for one week with rhVEGF-A165, the pre-
dominant human VEGF isoform, to stimulate endothelial
differentiation of BMSCs before injection into IHD patients
(NCT ID: NCT00644410) [18]. This study rendered the
procedure feasible and safe [19,20]. As recently submitted
by our group, a three-year follow-up found that patients
treated with VEGF-stimulated BMSCs had increased ex-
ercise capacity and improvements in clinical symptoms
compared to pre-treatment.
There are reports that ASCs can also differentiate into
endothelium in vitro and in animal ischemia models [21,22].
As a consequence of the results from the previous BMSC
trial and pre-clinical evidence for the beneficial use of
ASCs, the randomized double-blind placebo-controlled
MyStromalCell Trial was initiated (NCT ID: NCT01449032).
MyStromalCell Trial is the first in-man clinical trial that uses
culture-expanded ASC stimulated with rhVEGF-A165 a
week prior to cell therapy treatment in patients with
chronic myocardial ischemia and refractory angina [23].
Most previous and ongoing trials which have yielded
promising results, apply autologous stem cells from pa-
tients [24]. However, the potential effect of age and disease
on functional activity of the autologous stem cell pool is
debated, and conflicting results have been published
[25-28]. Our group found no difference in proliferation
or endothelial differentiation between BMSCs from car-
diac patients and healthy donors [29]. Human ASCs have
been found to have decreased population doublings and
markers of senescence with donor age [26]. However, a
recent study found that ASCs from aged donors exhibited
proliferation rates and osteogenic differentiation compar-
able to controls [28]. The only study investigating the
abilities of ASCs with regard to endothelial differentiation
from donors with heart disease, showed that it was feasibledespite the disease, but no comparison with healthy
controls was performed [30]. Therefore there is no exact
knowledge about the potential differences that might
exist between ASCs from patients with heart disease
and healthy donors. Furthermore, no studies have inves-
tigated the effect of VEGF treatment on ASCs and the
potential differences in this effect between ASCs from
IHD patients and healthy donors.
The present in vitro study investigated the effect of the
clinically applied VEGF pre-treatment of ASCs from IHD
patients and healthy donors. Differentiation of ASCs to-
wards endothelium after one, two, and three weeks of
VEGF stimulation and serum deprivation was evaluated
by identifying the presence of lineage specific markers on




ASCs from 7 IHD patients (all males, 58 to 76 years old,
mean age 65.7) enrolled in the placebo group of the
MyStromalCell Trial were used. All had coronary artery
bypass grafting and hyperlipidemia. One out of seven had
diabetes mellitus and two out of seven had hypertension.
In addition, ASCs from 7 healthy donors (2 male and 5
female, 28 to 57 years old, mean age 41.5) were used.
The protocol for the clinical study is in line with the
declaration of Helsinki, and approved by the National
Ethical Committee (H-3-2-2009-149) and the Danish
Medicines Agency (2612–2867). The inclusion and ex-
clusion criteria for the study can be found in the original
paper [23]. The use of adipose tissue from healthy vol-
unteers is approved by the National Ethical Committee
protocol no. H-3-2009-119.
Isolation of ASCs
Approximately 100 ml lipoaspirate was obtained from
liposuctions of subcutaneous abdominal fat performed
under local anesthesia. The lipoaspirate was washed twice
with phosphate buffered saline (PBS) pH 7.4 (GIBCO, Life
Technologies, UK) to remove residual blood. The adipose
tissue was digested by incubation with Collagenase NB
4 (SERVA Electrophoresis GmbH, Germany) dissolved
in HBSS (2 mM Ca2+, GIBCO, Life Technologies, UK)
at 37°C for 45 min. under constant rotation. The collage-
nase was neutralized with complete medium (Dulbecco’s
Modified Eagle Medium, low glucose 1 g/l supplemented
with 25 mM HEPES and L-Glutamin, PAA Labortatories,
Austria), 10% Fetal Bovine Serum pharma grade (FBS,
AA Labortatories, Austria), and 1% Penicillin/Streptomycin
(P/S, GIBCO, Life Technologies, UK) and filtered through
a 100 μl mesh (Cell Strainer, BD Bioscience, CA, US). The
remaining cells were centrifuged at 1200 g for 10 min.
at room temperature, re-suspended and counted using
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according to manufacturer’s instructions.
Cell culture
Cells were seeded in T75-flasks (Thermo Fischer Scientific,
MA, US) at a density of 4.5×106 cells/flask in complete
medium and incubated at standard conditions (37°C, 5%
CO2 humidified air). After two days in culture, cells were
washed to remove non-adhering cells. After approximately
a week in culture, cells were detached with TrypLE® Select
(GIBCO, Life Technologies, UK), resuspended, counted
on NucleoCounter®, frozen 1×106 cells/1 ml FBS with
5% DMSO (WAK-Chemie Medical GmbH, Germany)
at −80°C in Nalgene® Mr.Frosty freezing container (Sigma-
Aldrich, MO, US) and transferred to liquid nitrogen the
following day for storage [31].
When initiating an experiment, ASC were rapidly thawed
and seeded inT75-flask with media changed the follow-
ing day. When the cultures reached 80% confluence,
cells were passaged at 3×105 cells/T75-flask for the
experimental setup.
Human umbilical vein endothelial cells (HUVECs, Lonza,
Switzerland) were cultured as control cells for endothelial
markers. After thawing as described above, they were
cultured at 3×105 cells/T75-flask in endothelial growth
medium-2 (EGM-2, Lonza, Switzerland) and incubated
at 37°C and 5% CO2 with medium changed every three
days. Experiments were performed in passage 3.
Experimental VEGF protocol
ASCs were cultured in complete medium until 80%
confluence, after which medium was changed to either
complete medium, serum-deprived medium (DMEM added
2% FBS and 1% P/S) or serum-deprived medium added
50 ng/ml rhVEGF-A165 (rhVEGFA165, R&D Systems, MN,
US) (VEGF stimulation medium). Media was renewed
every three days and cells were cultured for one, two, or
three weeks after which they were harvested for further
processing.
Nucleic acid extraction
At the end of stimulation, cells were detached with
TrypLe and centrifuged at 300 g for 5 min. in RNase free
tubes (BD Biosciences, CA, US). To the cell pellet 350 μl
lysis buffer was added from the Qiagen RNeasy® Mini Kit
(QIAGEN Hamburg GmbH, Germany) and a 1 ml syringe
(B.Braun Melsungen AG, Germany) was used to lyse the
cells with lysis buffer before applying the rest of the
Qiagen protocol. Finally, total RNA was eluated with
RNase-free water (5 Prime GmbH Hamburg, Germany)
RNA purity was measured using a NanoDrop® 1000
Spectrophotometer (Thermo Scientific, MA, US), and
the eluate was stored at −80°C. RNA purity was validated
by absorbance ratios at 260 nm/280 nm and proteincontamination at A260/230. RNA integrity was con-
firmed by RIN values >8 using RNA Nano Chips
(Agilent Technologies, CA, US) and the Agilent 2100
Bioanalyzer with the instructions of the Agilent RNA
6000 Nano Kit.
Reverse transcription
cDNA synthesis was prepared using AffinityScript (Stratagene,
Agilent Technologies, CA, US) in a fast eight-tube strip
(0.1 ml, MicroAmp™, Applied Biosystems®, Life Technolo-
gies, UK) on ice. The total reaction volume was 20 μl with
0.5 μg RNA, 10 μl cDNA synthesis master mix, 3 μl Oligo
dT primer, 1 μl AffinityScript RT RNase block enzyme
mixture, and RNAase-DNAse free water (5 Prime
GmbH Hamburg, Germany) to 20 μl total volume. The
reactions were performed with an initial stage of 25°C
for 5 min., 42°C for 45 min., and 95°C for 5 min. (Veriti
96 well fast thermal cycler, Applied Biosystems®, Life
Technologies, UK). Following synthesis, cDNA was stored
in aliquots at −20°C.
Quantiative real-time PCR
Brilliant II SYBR®Green QPCR master mix with low
reference dye ROX (Agilent Technologies, CA, US) was
used with a total reaction volume of 25 μl in 96-well op-
tical reaction plates (Agilent Technologies, CA, US) with
5 μl of cDNA diluted 1:5 in 1× EDTA (QIAGEN Hamburg
GmbH, Germany) and subsequently 1:5 in RNAase-DNAse
free water (5 Prime GmbH Hamburg, Germany). The plate
was sealed with optical plastic caps (Agilent Technologies,
CA, US). qPCR was performed using Mx3000 (Stratagene,
AH-diagnostics, Denmark) and the results were collected
using Mx3000 version 4.0 software for Windows (Stratagene,
AH-diagnostics, Denmark). The reaction was initiated by
heating to 95°C for 10 min., followed by 40 cycles of
elongation at 60°C for 1 min. and denaturation at 95°C
for 30 sec.
Target and reference genes
The genes of interest were MSC marker CD105, endothelial
markers Forkhead box protein F1 (FOXF1),VEGF receptor 1
and 2 (VEGFR1 and VEGFR2), von Willebrand factor
(vWF) and CD31 with HUVECs as control (Table 1). To
verify the efficiency of each run, a calibration curve of
pooled cDNA diluted to fit a logarithmic curve was in-
cluded on each plate. Peptidylprolyl isomerase A (PPIA)
was selected as one of the most stable reference genes
from a larger panel including 18S rRNA, beta-actin,
elongation factor-1 alpha, glyceraldehyd 3-phosphate
dehydrogenase, beta-glucoronidase, ribosomal protein L13a,
TATA-binding protein, and tyrosine 3-monooxugenase/
tryptophan 5-monooxygenase activation protein zeta pep-
tide. The choice was based on stability both in terms of
donor variation and expression through the treatment.
Table 1 Genes of interest and reference gene for qPCR
Gene Full name GenBank accession
number
Forward (F) and Reverse (R) sequence Cellular function
CD105 Cluster of differentiation 105/ NM_000118.2 F = 5′-AACACCATCGAGCCGGG-3′ TGF-β signalling,
cytoskeletal organization
Endoglin R = 5′-GAACTCGGAGACGGATGGG-3′
VEGFR1 (FLT1) Vascular endothelial growth factor receptor 1
(FMS-like tyrosine kinase)
NM_002019.4 F = 5′-ATGCTGGATTGCTGGCACA-3′ Cell proliferation
and differentiation
R = 5′-TCAAACATGGAGGTGGCATT-3′
vWF von Willebrand Factor NM_000552.3 F = 5′-CGGCTTGCACCATTCAGC-3′ Hemostasis,
platelet adhesion
R = 5′-CCATCCTGGAGCGTCTCATC-3′
FOXF1 Forkhead box protein F1 NM_001451.2 F = 5′-CACTCCCTGGAGCAGCCGTATG-3′ Embryonic development,




Cluster of differentiation 31 NM_000442.4 F = 5′-ACAGCCTTCAACAGAGCCAAC-3′ Leukocyte migration,
angiogenesis
Platelet cell adhesion molecule 1 R = 5′-GAAAGAATGACTCTGACTGTCAGTATT-3′
PPIA Peptidyl prolyl isomerase A NM_021130.3 F = 5′-TCCTGGCATCTTGTCCATG-3′ Protein folding
R = 5′-CCATCCAACCACTCAGTCTTG-3′
Information for panel of chosen genes of interest and selected reference gene with full name, ncbi reference sequence, forward and reverse primer sequences,
and short description of cellular function.
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(Multid Analysis AB, Sweden). With the reference gene
software subprograms geNorm and Normfinder we
selected PPIA as the reference gene.
The fold changes in gene expression, normalized to
the mean of PPIA, were calculated using the ΔΔCq
method, with 2ΔΔCq as the fold change [32].
Gel electrophoresis
The presence of a single product from reference gene
and genes of interest was verified with dissociation curves
and by loading products from randomly selected qPCR
for gel electrophoresis. A 3% NuSieve 3–1 agarose (Lonza,
Switzerland) gel with 1× TAE buffer diluted from 50× TAE
buffer (QIAGEN Siences, MD, US). To visualize PCR
products, 10% non-toxic GelStar Nucleic Acid Gel Stain
(Lonza, Switzerland) was added to the gel. Electrophoresis
was performed in 1× TAE buffer. For every 8 μl PCR
product, 2 μl Gelpilot 5× loading dye (QIAGEN Siences,
MD, US) was added and loaded. A negative control was
included to evaluate contamination of the product.
Gelpilot 50 bp ladder and Gelpilot 1 kb ladder (both
QIAGEN Siences, MD, US) were used. The gel was run
between 70 and 100 volt in 45 – 60 min. and visualized
under ultraviolet light (Uvidoc, Uvitec Cambridge, MA, US).
Flow cytometry
ASCs from six subjects, (three healthy donors and three
IHD patients), stimulated one to three weeks as described
above, were detached using Accutase (PAA Laboratories,
Austria), centrifuged, counted, and frozen. On the day of
analysis, cells were thawed, washed in flow cytometry-PBS
containing FACS-PBS (Hospital pharmacy, Copenhagen,Denmark), 1% EDTA (Hospital pharmacy, Copenhagen,
Denmark), and 10% new born calf serum (GIBCO, Life
Technologies, UK) and counted. Cells were re-suspended
in flow cytometry-PBS, (1.5×105 cells/100 μl) and incu-
bated with or without initially titrated antibodies for
15 min. at room temperature. The antibodies were CD105-
phycoerythrin (PE) (R&D System, UK), CD90-flourescein
isothicyanate (FITC) (Beckman Coulter, Germany), CD73-
PE (BD Bioscience, NJ, US), CD13-phycoerythrin and
Texas Red (ECD) (Beckman Coulter, Germany), CD45-
phycoerythrin-cyanin (PC7) (Beckman Coulter, Germany),
CD34-allophycocyanin (APC) (Beckman Coulter, Germany),
CD19-ECD (Beckman Coulter, Germany), CD14-PC7
(Beckman Coulter, Germany), HLA-DR-FITC (Beckman
Coulter, Germany), VEGFR2-APC (R&D System, UK),
Tie-2-PE (R&D System, UK), CD144-APC (R&D System,
UK), CD31-PE (R&D System, UK). Isotypic controls used
were IgG2aFITC, IgG1-ECD, IgG1-APC, MsIgG1-PC7
(all Beckman Coulter, Germany), and IgG1-PE (BD
Bioscience, NJ, US) The cells were then centrifuged and
re-suspended in PBS. Viability was determined by adding
1 μl of SYTOX blue 7 min. prior to analysis (SYTOX®,
Invitrogen, Life Technologies, UK). HUVECs were used
as positive controls for endothelial markers. Expression
of endothelial markers and MSC characteristic surface
markers as suggested by the ISCT [33] was measured by
flow cytometry on a Navios flow cytometer (Beckman
Coulter, Germany) using a six-color protocol. The proto-
col was developed with manual compensation, isotypic
controls and Fluorescence Minus One. Dead cells and
doublets were excluded from the final analysis. Data was
analyzed using Navios software and Kaluza (Beckman
Coulter, Germany).
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MSC markers as well as markers for endothelial differ-
entiation were qualitatively assessed with immunofluores-
cence microscopy. Antibodies targeting stem cell markers
were CD73 (1:50, polyclonal rabbit anti-human, Abcam,
UK) and CD90 (1:100, monoclonal mouse anti-human,
Stemgent, MA, US) while those targeting endothelial
markers included vWF (ready to use, polyclonal rabbit
anti-human, DAKO, Denmark), Tie-2 (1:200, polyclonal
rabbit anti-human, Santa Cruz, TX, US), VEGFR2 (1:10,
polyclonal goat anti-human, R&D System, UK), CD144
(1:1000, polyclonal rabbit anti-human, Nordic BioSite,
Denmark), CD31 (1:100, monoclonal mouse anti-human,
DAKO, Denmark), and FOXF1 (1:75, polyclonal rabbit
anti-human, Abcam, UK).
ASCs from two healthy donors and two IHD patients
were seeded at a density of 3×103 cells/cm2 in four-
chamber PermanoxTM chamberslides (Lab-Tek™ Chamber
Slides, ThermoFisher Scientific, MA, US). Cells were
treated with the three different media types for one, two
and three weeks. Cultures were fixated with 4% Parafor-
maldehyde in PBS pH 7.4 (Hospital pharmacy, Denmark)
for ten minutes. Unspecific binding was blocked with 2%
Bovine Serum Albumin (BSA, Sigma Aldrich, MO, US).
Primary antibodies were diluted according to initial titra-
tion in 1% BSA and cells were incubated with primary
antibodies overnight at 4°C. Secondary antibodies were
added for one hour at room temperature shielded from
light. Secondary antibodies were Alexa Fluor® 555 goat
anti-rabbit IgG, Alexa Fluor® 568 goat anti-rabbit IgG,
Alexa Fluor® 568 goat anti-mouse IgG, Alexa Fluor® 555
goat anti-mouse IgG, Alexa Fluor® 568 donkey anti-goat
(1:250, all from Invitrogen, Life Technologies, UK).
Primary antibodies were omitted in control wells to test
secondary antibody specificity. Positive controls were done
on HUVECs seeded 3×103 cells/well in four-well chamber
slides in EGM-2 medium (EGM-2 Bulletkit, Lonza,
Switzerland) two days prior to fixation. After secondary
antibody incubation, chambers were removed and the
slides carefully washed and dried. ProLong Gold antifade
reagent with DAPI (Molecular Probes®, Invitrogen, Life
Technologies, UK ) was used to stain for nuclei and mount
the slides with cover slips (Menzel-Glaser, Germany).
Pictures were taken at 20× or 40× objective with an
Olympus IX51 microscope and an Olympus DP71 digital
camera and Olympus U-RFL-T fluorescence system. Image
analysis was performed with ImageProPlus 7.0 (Media
Cybernetics).
In vitro angiogenesis assay
An ECMatrix® in vitro angiogenesis assay (In VitroAngiogenesis
Assay Kit, Millipore, MA, US) was performed to test the
ability of ASCs to form tubules. ASCs from three healthy
donors and three IHD patients were stimulated asdescribed above. Cells were seeded in duplicate wells in
150 μL of their respective media in a 96-well plate (Nunc,
Thermo Scientific, MA, US) with 1×104 cells/well on
ECMatrix® prepared according to manufacturer’s instruc-
tions. Following seeding of cells, 96-well plates were incu-
bated at 37°C with 5% CO2 for 20 hours. Every four hours,
three representative pictures were taken in each well using
a phase contrast Olympus IX51 microscope equipped with
an Olympus TL4 halogen light source and an Olympus
DP71 digital camera. Image analysis was performed with
ImageProPlus 7.0 (Media Cybernetics). For each picture,
tube formation was quantified blinded, by manually
counting number of polygons formed defined as areas
enclosed by tube-like structures.
Proliferation assay
Proliferation was assessed using Bromodeoxyuridine (BrdU)
cell proliferation ELISA Kit (Roche®, Switzerland). ASCs
from three healthy donors and three IHD patients were
seeded in 96-well plates, 1.0×103 cells/well in triplicate
in complete medium. After adhering overnight, 10 μM
BrdU was added to each well. Media and BrdU labeling
was changed on day two, and additional BrdU was added
to the media on day three. Fixing, labeling and washing
were performed according to manufacturer’s instructions.
After stopping the substrate reaction with 25 μL 1 M
2 N H2SO4 (vWR, PA, US) for one minute on a shaker
(IKA VIBRAX VXR basic), the absorbance was measured
with a Microplate Reader (BioRad, Model 680, CA, US)
at wavelength 450 nm and reference wavelength 655 nm.
BrdU incorporation was measured at hours 24, 48, 72,
and 96.
Statistics
For qPCR data normality was assessed graphically by
comparison to normally distributed generated data in
Microsoft® Office Excel® 2007, with all other data analysis
being performed in IBM SPSS and SigmaPlot. For
ECMatrix and flow cytometry data, distribution was
determined using Kolmogorov-Smirnov and Shapiro-Wilk
tests for normality. A mixed model repeated measures
ANOVA was performed for qPCR data, in vitro angiogen-
esis data, flow cytometry data, and BrdU proliferation data
with p < 0.05 considered significant.
Results
Transcription of endothelial markers FOXF1, vWF, and VEGFR1
We found that transcription of endothelial markers FOXF1,
vWF, and VEGFR1 were significantly up-regulated in
serum-deprived and VEGF-stimulated ASCs compared
to cells cultured in complete medium (Figure 1). There
was no overall effect of donor health status on tran-
scriptional activity, however we observed a tendency of
lower expression of endothelial markers in week two
Figure 1 Gene expression levels by quantitative real-time PCR analysis of ASCs. Expression of FOXF1 (A), vWF (B), VEGFR1 (C), CD31 (D), and
CD105 (E) in ASCs at passage two from both IHD patients (n = 7) and healthy donors (n = 7) in serum-deprived medium or VEGF stimulation medium.
The expression of a gene is shown as fold change compared to expression of the same gene in ASCs from the same donor in complete medium, and has
been calculated by the ΔΔCq-method. Significant difference (p< 0.05) compared to complete medium is shown by * above the column, while a
significant difference (p<0.05) between the different weeks of culture is shown by §. ASCs; Adipose-derived stromal cells, IHD; ischemic heart disease,
FOXF1; Forkhead box protein F1, vWF; von Willebrand factor, VEGFR1; vascular endothelial growth factor receptor 1, CD; Cluster of differentiation. Mean± SEM.
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medium, expression levels of the early marker for endo-
thelial differentiation FOXF1 were significantly increased
(p < 0.05) in ASCs when cultured in serum-deprivedmedium and VEGF stimulation medium for IHD patients
for the three weeks tested. FOXF1 was also significantly
increased in ASCs from healthy donors at week one and
three of culture (Figure 1A). The expression of endothelial
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ASCs in VEGF stimulation medium after week one and
three, and additionally for IHD patients in serum-
deprived medium at week three (Figure 1B). The expres-
sion of VEGFR1 was significantly increased (p < 0.05) for
all ASCs in serum-deprived medium and VEGF stimula-
tion medium at week three, and also after week one for
healthy donor ASCs (Figure 1C). Transcription of stem
cell marker CD105 and endothelial marker CD31 were
not significantly affected by type of media, time in culture
or donor health status , though we observed an insignifi-
cant trend of CD31 increased only in week one (Figure 1D
and E). VEGFR2 was very low expressed, with large
variance between technical replicates and was therefore
excluded. HUVECs were positive for endothelial markers.
The Cq values for VEGF stimulated ASCs and HUVECs,
respectively, were 31.0 ± 1.0 and 23.1 for FOXF1, 30.4 ± 1.3
and 26.2 for vWF, 30.8 ± 1.4 and 27.1 for VEGFR1, 21.0 ±
1.1 and 19.4 for CD105, and 33.0 ± 1.6 and 21.6 for CD31.Persistent stem cell characteristics on flow cytometry
We found that MSC characteristic markers as defined by
ISCT, were unaffected by VEGF treatment, donor health
status or time in culture. Therefore, Figure 2A showing
data from donors and patients is representative for all
weeks. Likewise, Figure 2B depicting expression from
week one in ASCs from a healthy donor is representative
for all weeks and donor health status. Positive MSC CD105,
CD73, and CD13 were all expressed at a level around 95%,
while CD90 expression was around 80%. Expression of
the markers HLA-DR, CD19, and CD14 was below 2%,
while the expression level of CD45 and CD34 was between
2% and 8%. Endothelial markers, CD31, VEGFR2, CD144
and Tie2 were below 2% in expression levels, while these
were at the levels of 99%, 76%, 27%, and 59% for HUVEC
controls, respectively. The ASC population is shown on a
scatter plot together with representative overlay plots for
each marker in Figure 2B.Visualization of endothelial and stem cell markers by
immunocytochemistry
Protein expression was visualized with immunocyto-
chemistry by staining for endothelial markers FOXF1,
VEGFR2, vWF, Tie-2, CD144, CD31, and MSC markers
CD90 and CD73. Both of the MSC markers were present
across all weeks, culture conditions and donors, shown
with representative images from healthy donors week
one in Figure 3A. All endothelial markers were identified
on positive control cells (HUVEC). However, on ASCs we
found only sporadic unsystematic staining of endothelial
markers across all weeks, culture conditions and donors.
Figure 3B presents the positive sporadic expressions on
ASCs together with HUVEC controls.Serum-deprivation has a positive effect on in vitro
angiogenesis
A clear difference in tube formation was observed for
ASCs in serum-deprived medium and VEGF stimulation
medium compared to complete medium which contrib-
uted with little to no tubulogenesis (Figure 4A). ASCs in
complete medium gathered in spheres rather than tubes,
and polygons were seldom observed. Both patient and
healthy donor ASCs showed the greatest tube formation
after four hours. Calculated mean numbers of polygons
presented no difference in tube formation between ASCs
from serum-deprived medium and VEGF stimulation
medium from either IHD patients or healthy donors
(Figure 4B). Therefore serum deprivation seems to be
the decisive factor with regard to tube formation for
ASCs on ECMatrix®. ASCs were able to form the same
amounts of polygons as HUVEC controls, and though
the HUVEC polygons seemed slightly more stable at eight
hours, their tube formation followed the same pattern as
the ASCs.
Decreased proliferation rate for ASCs from IHD patients
The proliferation rate was measured with BrdU incorp-
oration over 96 hours for ASCs from three IHD patients
and three healthy donors in complete medium. IHD
patient ASCs exhibited significantly (p < 0.05) lower pro-
liferation after 72 and 96 hours, measured as fold change
from 24 hours (Figure 5). The slopes of the curves suggest
a generally increased population doubling for ASCs from
healthy donors resulting in the significant difference
at 72 hours. This difference remained at 96 hours, though
the proliferation of ASCs from both groups had stopped.
The results only reflect proliferation, while the viability
was not measured.
Discussion
In the clinical MyStromalCell Trial the aim is to revas-
cularize ischemic myocardial tissue by injection with
ASCs that have been pre-treated with VEGF in vitro for
one week, in order to improve in vivo angiogenic or
vasculogenic function. We investigated the effect of such
in vitro VEGF treatment in combination with serum
deprivation for up to three weeks of ASCs from IHD pa-
tients and healthy donors with regard to differentiation
towards an endothelial lineage. MSC and endothelial
markers were tested for gene expression and protein
levels, while functional tube formation and proliferation
assays contributed to further characterization. The present
in vitro study shows that pre-treatment of ASCs can guide
these cells towards endothelial behavior, with serum
deprivation and not VEGF as the decisive factor.
With regard to upregulation of markers FOXF1 and
VEGFR1, serum deprivation proved equally efficient alone
and in combination with VEGF. Serum deprivation did
Figure 2 Detection of ASC surface marker expression by flow cytometry. Mean expression percentage of stem cells markers CD105, CD90,
CD73, and CD13, immune stimulation marker HLA-DR, leukocyte marker CD45, endothelial progenitor marker CD34, B-cell marker CD19, monocyte marker
CD14, and endothelial markers CD31, CD144, Tie-2, and VEGFR2 (A). Data is from the first week of stimulation for ASCs in passage three. A representative
scatterplot and histograms from one healthy donor (B) for positive (white) and non-positive (grey) populations. The population shown on the scatterplot
consists only of viable cells, while the remaining dead cells are gated out with the use of SYTOX dead cell stain. Isotypic controls were used during
implementation and proved no unspecific staining. ASCs; Adipose-derived stromal cells, IHD; Ischemic heart disease, CD; cluster of differentiation, HUVEC;
human umbilical vein endothelial cell, HLA-DR; Human leukocyte antigen-DR, Tie-2; TEK tyrosine kinase endothelial-2, VEGFR2; vascular endothelial growth
factor receptor 2. N = 3 for ASCs and n = 1 for HUVECs. Mean ± SEM.
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Figure 3 Stem cell expression visualized by fluorescent immunocytochemistry. Representative pictures from a healthy ASC donor for CD90
and CD73 visualized at × 40 for all media types (A). Pictures of the sporadic positivity for some of the endothelial markers at × 40 against HUVEC
controls at × 20 (B). ASC; Adipose-derived stromal cell, CD; Cluster of differentiation, HUVEC; human umbilical vein endothelial cell.
Follin et al. Journal of Translational Medicine 2013, 11:219 Page 9 of 14
http://www.translational-medicine.com/content/11/1/219not produce the same effect as VEGF treatment, in
terms of vWF expression after one and three weeks of
stimulation for healthy donors. This could be attributedto a genuine effect of VEGF. However, since the difference
between the VEGF treatment and the serum-deprivation
is not significant and as this is the only marker and time
Figure 4 Tube formation of ASCs after 4 hours on ECMatrix. Representative pictures of ASCs from IHD patients and healthy donors in
complete medium, serum-deprived medium, and VEGF stimulation medium (A). Timeline of generated number of polygons after one week of
stimulation, representative for all weeks, with HUVEC reference timeline (B). N = 3 for ASCs and n = 1 for HUVECs. ASC; Adipose-derived stromal
cells, IHD; ischemic heart disease, HUVEC; human umbilical vein endothelial cell.
Follin et al. Journal of Translational Medicine 2013, 11:219 Page 10 of 14
http://www.translational-medicine.com/content/11/1/219point which differs between the two treatments, we
cannot exclude this as a figment of donor variation. We
included the transcription factor FOXF1 as an early marker
of endothelial differentiation, because its activation in
the mesoderm leads to VEGFR2 expression and activa-
tion of vascular tube formation [34]. The precise func-
tions of FOXF1 have not yet been elucidated, but it has
been implicated in endothelial-mesenchymal transition
[35-37]. The co-expression of FOXF1, vWF, and VEGFR1
in our experiment, indicates that it is implicated in early
stage differentiation towards endothelial lineage, possibly
through cell cycle control needed for differentiation to
occur [36].
We failed to identify expression of VEGFR2 on ASCs
in all tested circumstances. These data are in compliance
with Ball et al. who found neither VEGFR2 nor VEGFR1
on BMSCs [38]. VEGFR2 has a function in cell migration
and proliferation with regard to angiogenesis whereas the
specific functional effect of VEGFR1 is less well known[39,40]. It has been suggested that VEGFR1 is a negative
regulator of VEGF-A/VEGFR2 signaling and can regulate
signaling through VEGFR2 by binding and sequestering
VEGF-A, to which VEGFR1 has a higher affinity than
VEGFR2 [39-43]. It has also been proposed that VEGFR1
is a positive regulator of sprout formation and migration,
possibly by negative control of the amount of VEGF-A
sensed by the cells, which could explain our observations
of VEGFR1 increase and enhanced sprouting in serum-
deprived conditions [40,44].
We found a general tendency for lower expression of
all endothelial markers after the second week in culture.
Inadequate stimulation may cause a transient feedback
mechanism, resulting in the observed decrease in endo-
thelial gene expression in week two. The lack of a con-
tinuous increase in expression during weeks in culture
supports the idea that serum-deprivation only prepares the
ASCs for differentiation but is insufficient to fully differ-
entiate the ASCs toward endothelium, and even prolonged
Figure 5 ASC proliferation over four days. Comparison between proliferation of ASCs from IHD patients (yellow) (n = 3) and healthy donors
(green) (n = 3) using colorimetric BrdU proliferation assay measured by absorbance at 450 nm, reference 655 nm, at 24, 48, 72, and 96 hours, and
normalized to 24 hours. ASCs; adipose-derived stromal cells, BrdU: Bromodeoxyuridine, IHD; ischemic heart disease Mean +/- SEM.
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stimuli to carry the process through.
Immunocytochemistry with endothelial markers resulted
in only sporadic staining independent of stimulation, time
in culture and donors, even with the markers clearly up
regulated at the transcriptional level. Acknowledging the
heterogeneity of the population, however homogenous it
appears according to the ISCT criteria, differences found
in transcriptional activity might reflect changes in only a
small subset of ASCs and not the population in general
[45,46]. However, the sporadic staining was also observed
in ASC cultured in complete medium, and did not correl-
ate with the qPCR results. A more general subpopulation
could be caused by endothelial cell contamination, which
would explain the sporadic staining. An equally plausible
explanation is that translation of given endothelial markers
and receptors is never completed, but mRNA modulated
due to lack of sequential stimuli in this in vitro scenario.
The fact that the ASCs readily form tubules when
seeded on ECMatrix® in serum-deprived medium with
and without VEGF demonstrates that they are capable of
behaving like endothelial cells and on an initial level of
tube formation similar to HUVEC controls, but need
other stimuli, such as the ECMatrix® substrate, in addition
to serum-deprivation and/or VEGF stimulation to commit
to differentiation. Since there was no tubule formation
in complete medium and ASCs did not spontaneously
form tubules in the regular culture dish during serum-
deprivation, neither ECMatrix® nor serum-deprivation is
independently sufficient to stimulate ASCs to form tubules,emphasizing the need for multiple stimuli. This is sup-
ported by publications from several other groups which
have successfully differentiated ASCs toward endothelial
lineage with VEGF treatment but always in combination
with additional factors. [30,47]. A multitude of parameters
including endothelial cell growth supplements, shear
force, three-dimensional culture and supporting matri-
ces have also been found essential when addressing full
endothelial differentiation of ASCs and BMSCs respect-
ively [48-50].
The proliferation curve obtained from the BrdU incorp-
oration assay suggests a slower population doubling of
ASCs from IHD patients compared to those from healthy
donors, which is similar to what others have found
[27,51]. However, since there were no observed differ-
ences in the other measured parameters of the study, we
conclude that the difference between ASCs from healthy
donors and IHD patients is minimal, and only signifi-
cant for proliferation.
ASCs retained their MSC characteristics defined by
ISCT criteria under all tested circumstances as shown by
flow cytometry. This was supported by the unaffected
translation of CD105 as well as protein expression of
CD90 and CD73 identified with immunocytochemistry.
The expression percentages of the MSC markers closely
resemble the percentages presented in the ISCT criteria
[33,52]. We obtained a larger than expected percentage
of CD45+ cells. This was found to be related to samples
with low viability by observing a high percentage of
SYTOX® uptake in the same samples. The close correlation
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unspecific CD45 labeling of dead and thereby permeable
cells. Dead cells did not interfere with results for other
markers. Taking this into consideration, patient and donor
ASCs retain their MSC characteristic markers defined by
ISCT stem cell definition standards, during culture with
the different types of media including treatment withVEGF.
The observed impact of serum-deprivation is consistent
with a recent study performed on BMSCs, where the cells
that were serum-deprived over a longer period of time
exhibited an endothelial phenotype, with an upregulation
of angiogenic markers [53]. The limited response in
upregulation of classical endothelial markers after VEGF
stimulation and serum deprivation of the ASCs was
not expected, since Haack-Sorensen et al. successfully
induced the expression of VEGFR2, vWF and CD31
mRNA and protein in BMSCs after a week in culture
under identical circumstances [15]. This calls attention
to the fact that BMSC and ASCs are not analogous,
though this remains to be investigated in a side-by-side
comparative study. However, endothelial differentiation
of ASCs seems plausible provided more factors are present.
The equal responses of the ASCs from healthy donors
and IHD patients do not favor one over the other in terms
of future allogenic or autologeous transplants.
The study has certain limitations. The controls for
endothelial phenotype were HUVECs, while a more
suitable control for this study could have been fully dif-
ferentiated endothelial precursor cells derived from ASCs,
using a more effective protocol [49]. In addition, we did
not actively deplete endothelial cell contamination during
ASC isolation. Though we rely on a previously established
protocol, which has shown elimination of endothelial
markers during culture, such endothelial cells could be
speculated to perform endothelial-to-mesenchymal transi-
tion which could be reversible [15,54]. In terms of endo-
thelial marker expression this could explain the subtle
response on transcription and the sporadic appearance of
markers with immunocytochemistry, while the percentage
of cells remained below the 2% detection threshold for
flowcytometry. The donor groups were not matched with
age and sexes, which could give rise to selection bias. Dif-
ferences in proliferative properties due to age have been
reported, but the authors could not find data on gender
differences in ASCs abilities [26]. The effect of co-
morbidities was not investigated, since the results obtained
were very similar in the IHD patient group. Finally, there
has in recent years been a shift in paradigm in the field
of stem cell research, towards the ASC secretome as the
main contributor in stem cell therapy [55-57]. Enhancing
pro angiogenic paracrine properties of ASCs has been
achieved by different approaches [58,59]. In fact, a recent
study by Yan et al., found that VEGF-stimulated ASCs
secreted increased amounts of VEGF themselves [59].Thus, the cell-free conditioned medium from present
study should be addressed in future studies with regards
to potential differences in the secreted amounts of
angiogenic growth factors.Conclusions
Our study found evidence of ASC differentiation in progress
towards an endothelial lineage upon serum-deprivation, but
we found no additional visible effect of VEGF stimulation or
prolonged time in culture. The stimulatory effect of serum
deprivation was subtle, with significant increase of only
the earliest markers of endothelial differentiation on mRNA
level. Serum-deprived ASCs however readily form tube-like
structures on ECMatrix® even though traditional stem cell
markers are maintained under all conditions. We did not
find any difference between ASCs from healthy donors and
IHD patients with regard to their in vitro differentiation
capacity or retention of stem cell characteristics, but ob-
served a slight difference in proliferative abilities.
Our study was conducted in support of the ongoing
clinical MyStromalCell Trial. Though final endothelial
differentiation of ASCs is not obtained during in vitro
cultivation, we find it plausible that the demonstrated
in vitro priming facilitates angiogenesis upon in vivo deliv-
ery into an environment with the necessary multi-factorial
and three-dimensional setting. In terms of endothelial prim-
ing for future studies, it is not advantageous to use VEGF as
an independent supplement, since it is expensive and no
more effective than serum-deprivation.Consent
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